CDT Equity (CDT) Cash from Operations (2022 - 2026)
CDT Equity's (CDT) quarterly Cash from Operations came in at -$4.3 million in Q2 2026, down 68.14% on a YoY basis from -$13.6 million in Q2 2025, and down 328.32% quarter-over-quarter from $1.9 million in Q1 2026.
Analysis
CDT Equity (CDT) Cash from Operations (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has reported Cash from Operations for 5 consecutive years, with -$4.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Operations fell 68.14% year-over-year to -$4.3 million; the trailing twelve-month figure through Jun 2026 stood at -$11.5 million (up 6.34% YoY), and the FY2025 full-year result was -$15.6 million, down 60.82% from the prior year.
- Cash from Operations slipped to -$4.3 million in Q2 2026 per CDT's latest filing, from $1.9 million in the prior quarter.
- Across five years, Cash from Operations topped out at $1.9 million in Q1 2026 and bottomed at -$4.8 million in Q4 2023.
- Historically, Cash from Operations has averaged -$2.1 million across 5 years, with a median of -$2.0 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Cash from Operations tumbled 433.67% in 2023, then soared 148.36% in 2026.
- Over 5 years, Cash from Operations stood at -$900000.0 in 2022, then sank by 433.67% to -$4.8 million in 2023, then increased by 20.88% to -$3.8 million in 2024, then slipped by 23.18% to -$4.7 million in 2025, then gained by 7.33% to -$4.3 million in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered -$4.3 million, $1.9 million, and -$4.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 835.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 3.44 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -387.32 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 507.66 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 313.60 Mn |
| 10 | CDT Equity | 187,135.95 | 187,135.95 | - | -4.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.34 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Sep 30, 2025 | -4.41 Mn |
| Jun 30, 2025 | -2.58 Mn |
| Mar 31, 2025 | -3.93 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -2.00 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | -522,000.00 |
| Jun 30, 2023 | -400,000.00 |
| Mar 31, 2023 | -2.00 Mn |
| Dec 31, 2022 | -900,000.00 |
| Sep 30, 2022 | -580,600.00 |
| Jun 30, 2022 | -126,915.00 |
| Mar 31, 2022 | -692,485.00 |